Nxstage Medical, Inc. (NXTM) Tops Q2 EPS by 1c; Guides Wider Q3 Loss; Gets EU Approval for New Bolus Use
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Join SI Premium – FREE
Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q2 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $59 million versus the consensus estimate of $58.22 million.
Nxstage Medical, Inc. sees Q3 2012 EPS of $-0.08-$-0.06, versus the consensus of $-0.05. Nxstage Medical, Inc. sees Q3 2012 revenue of $60-$61 million, versus the consensus of $61.93 million.
Separately, the Company announced that the European regulatory authority has approved a new feature to automate the administration of bolus for use in the EU.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Nxstage Medical, Inc. sees Q3 2012 EPS of $-0.08-$-0.06, versus the consensus of $-0.05. Nxstage Medical, Inc. sees Q3 2012 revenue of $60-$61 million, versus the consensus of $61.93 million.
Separately, the Company announced that the European regulatory authority has approved a new feature to automate the administration of bolus for use in the EU.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Oceaneering (OII) Tops Q1 EPS by 5c, confirms prior guidance
- FS Bancorp (FSBW) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
Earnings, FDA, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
